CRBU logo

CRBU
Caribou Biosciences Inc

2,714
Mkt Cap
$186.51M
Volume
821,296.00
52W High
$3.54
52W Low
$0.71
PE Ratio
-1.21
CRBU Fundamentals
Price
$1.93
Prev Close
$1.96
Open
$1.96
50D MA
$1.80
Beta
1.86
Avg. Volume
1.12M
EPS (Annual)
-$1.59
P/B
1.50
Rev/Employee
$115,041.24
$36.38
Loading...
Loading...
News
all
press releases
Caribou Biosciences' (CRBU) Buy Rating Reaffirmed at HC Wainwright
HC Wainwright reiterated a "buy" rating and set a $9.00 price target on shares of Caribou Biosciences in a research report on Tuesday...
MarketBeat·5d ago
News Placeholder
More News
News Placeholder
Alpha Cognition Inc. (ACOG) Soars 8.6%: Is Further Upside Left in the Stock?
Alpha Cognition Inc. (ACOG) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Zacks·10d ago
News Placeholder
Sarepta Therapeutics (SRPT) Soars 35.0%: Is Further Upside Left in the Stock?
Sarepta Therapeutics (SRPT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Zacks·17d ago
News Placeholder
Caribou Biosciences (NASDAQ:CRBU) Stock Rating Upgraded by Truist Financial
Truist Financial raised shares of Caribou Biosciences to a "strong-buy" rating in a research report on Wednesday...
MarketBeat·18d ago
News Placeholder
Is CareCloud (CCLD) Outperforming Other Medical Stocks This Year?
Here is how CareCloud, Inc. (CCLD) and Caribou Biosciences, Inc. (CRBU) have performed compared to their sector so far this year.
Zacks·27d ago
News Placeholder
Caribou Biosciences Teases vispa-cel Phase 3 LBCL Plan, Eyes Financing at Leerink Conference
Executives from Caribou Biosciences (NASDAQ:CRBU) outlined upcoming clinical, regulatory, and financing milestones for its allogeneic cell therapy pipeline during a discussion at the Leerink Global...
MarketBeat·29d ago
News Placeholder
Caribou Biosciences, Inc. (CRBU) Reports Q4 Loss, Tops Revenue Estimates
Caribou Biosciences (CRBU) delivered earnings and revenue surprises of +14.11% and +56.02%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·1mo ago
News Placeholder
Caribou Biosciences (NASDAQ:CRBU) Posts Earnings Results, Beats Estimates By $0.05 EPS
Caribou Biosciences (NASDAQ:CRBU - Get Free Report) posted its quarterly earnings data on Thursday. The company reported ($0.28) earnings per share for the quarter, beating analysts' consensus...
MarketBeat·1mo ago
News Placeholder
EyePoint (EYPT) Reports Q4 Loss, Tops Revenue Estimates
EyePoint (EYPT) delivered earnings and revenue surprises of -3.85% and +15.89%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·1mo ago
News Placeholder
Urogen Pharma (URGN) Reports Q4 Loss, Beats Revenue Estimates
Urogen Pharma (URGN) delivered earnings and revenue surprises of +18.18% and +6.42%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·1mo ago
<
1
2
...
>

Latest CRBU News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.